glp-1 receptor agonist atrial fibrillation risk Glucagon‐like peptide‐1 semaglutide reduces incidence: A systematic review and meta‐analysis - Saglietto - 2024 - European Journal of Clinical Investigation If you take a GLP-1

Anyways, teach us, Carley

In addition, the gut-derived metabolite imidazole propionate has been shown to drive -synuclein pathology in preclinical and patient-derived PD models, providing a direct link between dysbiosis and -synuclein aggregation (103)

412 Notably, GLP-1RAs, including exendin-4, have been shown to attenuate microglial activation, resulting in a reduction in the expression of proinflammatory cytokines such as TNF- and IL-1

The approval arrives at a surreal moment for Lilly

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm

TREATMENT with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia and Alzheimers disease in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), according to a new retrospective cohort study